◀ Back to IGF1
IGF1 — SDS
Text-mined interactions from Literome
Moorkens et al., Growth Horm IGF Res 1998
(Body Weight...) :
Mean ( +/- SD ) serum levels of
insulin-like growth factor I (IGF-I) increased during GH treatment, from 173 +/- 46 microg/I to 296 +/- 89 microg/l ( P < 0.001 ) ; IGF-I
SDS values increased from -0.45 +/- 1.14 to +1.43 +/- 1.09 ( P < 0.001 )
Rite et al., Pediatr Res 2002
(Gaucher Disease...) :
Total IGF-I
SDS increased from -1.8 +/- 0.8 to -0.8 +/- 1.4 ( p = 0.005 ) and free
IGF-I increased from -1.2 +/- 1 to 1.1 +/- 2.1 after 12 +/- 6.8 mo ( p = 0.011 ) of ERT
Bannink et al., J Clin Endocrinol Metab 2007
:
During GH therapy, free
IGF-I significantly
increased to 1.6 ( 0.7 )
SDS , as did total IGF-I and IGFBP-3 [ 2.0 ( 0.8 ) and 1.3 ( 0.9 ), respectively ]
Aydogan et al., Int J Pediatr Otorhinolaryngol 2007
(Hypertrophy...) :
However, the mean serum
IGF-1 level increased from 80.3+/-48.5 to 116.8+/-105.9ng/ml ( p : 0.135 ), and IGF-1
SDS increased from -1.36+/-0.51 SDS to -1.31+/-1.14 SDS ( p : 0.701 ), which were both not statistically significant
Yordam et al., Eur J Endocrinol 1995
(Body Weight...) :
The diagnosis based on height
standard deviation score (SDS) , basal growth hormone (GH), basal
insulin-like growth factor I ( IGF-I, IGF-I
response in an IGF generation test and growth hormone binding protein (GHBP) measurements